Immunization with rAd encoding 168NP before scrapie inoculation significantly prolonged the survival of infected mice. This effect was attributable to a significant lengthening of the symptomatic phase and was associated with enhanced CD3 + T cell recruitment to the CNS. However, immunization with Ad168NP in scrapie-incubating mice induced IFNc-secreting CD8 + T cells that were not cytolytic in vivo and did not influence disease progression nor infiltrated the brain. In conclusion, the data suggest that vaccine-induced PrP-specific CD8 + T cells interact with prions into the CNS during the clinical phase of the disease.
partially protect scrapie-infected mice from disease, the potential autoreactivity of CD8 + cytotoxic T lymphocytes (CTLs) received little attention. Beneficial or pathogenic influence of PrP c -specific CTL was evaluated by stimulating a CD8 + T-cell-only response against PrP in scrapie-infected C57BL/6 mice. To circumvent immune tolerance to PrP, five PrP-derived nonamer peptides identified using prediction algorithms were anchored-optimized to improve binding affinity for H-2D b and immunogenicity (NP-peptides). All of the NP-peptides elicited a significant number of IFNc secreting CD8 + T cells that better recognized the NP-peptides than the natives; three of them induced T cells that were lytic in vivo for NP-peptide-loaded target cells. Peptides 168 and 192 were naturally processed and presented by the 1C11 neuronal cell line. Minigenes encoding immunogenic NP-peptides inserted into adenovirus (rAds) vectors enhanced the specific CD8 + T-cell responses. Immunization with rAd encoding 168NP before scrapie inoculation significantly prolonged the survival of infected mice. This effect was attributable to a significant lengthening of the symptomatic phase and was associated with enhanced CD3 + T cell recruitment to the CNS. However, immunization with Ad168NP in scrapie-incubating mice induced IFNc-secreting CD8 + T cells that were not cytolytic in vivo and did not influence disease progression nor infiltrated the brain. In conclusion, the data suggest that vaccine-induced PrP-specific CD8 + T cells interact with prions into the CNS during the clinical phase of the disease. Ó 2012 Elsevier Inc. All rights reserved.
Introduction
Prion diseases are fatal transmissible neurodegenerative diseases in which a host-encoded protein, the cellular prion protein (PrP c ), is converted into an abnormally folded isoform called PrP Sc .
PrP
Sc is the main or only component of the infectious agent (Prusiner et al., 1998; Ma and Lindquist, 2002) . These diseases are characterized by a long and asymptomatic peripheral incubation period followed by rapidly progressive and severe neurological dysfunctions and by specific pathological lesions of the CNS. To date, no cure has been found for prion diseases. Recently, immunotherapeutic approaches have been developed in experimental model of neurodegenerative diseases with some success (Peretz et al., 2001; White et al., 2003; Polymenidou et al., 2004; Schenk et al., 1999; Rosset et al., 2009) . PrP antibodies inhibit the conversion of PrP c to PrP Sc in vitro (Beringue et al., 2004; Pankiewick et al., 2006) and confer some degree of protection against murine scrapie in vivo (Peretz et al., 2001; White et al., 2003; Polymenidou et al., 2004 ). Yet, they have been effective only during the peripheral lymphoreticular phase of the disease, presumably as a result of their poor blood-brain barrier penetration. 
